Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade.
Focal tumor cell PD-L1 expression adjacent to TIL can be used as a surrogate marker of an ongoing antitumor host response, which may be unleashed by PD-1 blockade. Tumor cell PD-L1 expression is superior to TIL PD-1 expression and the presence of TIL alone, when predicting response to anti-PD-1 therapy.
Departments of Dermatology; Pathology, and Oncology; Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center ; Baltimore, MD USA.
Janis M
JM
Taube
CRPC, castration-resistant prostate cancer; FFPE, formalin-fixed paraffin-embedded; NSCLC, non-small cell lung carcinoma; PD-1; PD-1, programmed death 1; PD-L1; PD-L1, programmed death-ligand 1; PD-L2; PD-L2, programmed death-ligand 2; RCC, renal cell carcinoma; TIL, tumor-infiltrating lymphocytes; cancer immunotherapy; tumor microenvironment